Skip to main content

Avadel Pharmaceuticals PLC

AVDLDelisted Feb 12, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001012477

Avadel Pharmaceuticals PLC was delisted on Feb 12, 2026; its insiders filed their last Form 4 on Feb 18, 2026; 208 institutions reported holding it in 13F filings for Q4 2025, worth $1.60B in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
208
Q4 2025, +21 vs. previous quarter
13F value
$1.60B
Reported value at the end of Q4 2025
Superinvestors holding
0
At the end of Q4 2025

Superinvestors holding AVDL, Q4 2025

Go to the superinvestors tab

No superinvestor reported holding AVDL at the end of Q4 2025.

Latest insider trades

Open-market purchases and sales by Avadel Pharmaceuticals PLC insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 18, 2026 (view filing)5:18 PM ETFeb 135 daysWeiss Asset Management LP and 1 otherOther: Former 10% OwnerSSale−11.1M$21.00−$233.4M−100.0%0 after
Jan 22, 2025 (view filing)Jan 211 dayPalczuk LindaDirectorPPurchase+5.00K$7.93+$39.6K+7.9%67.9K after
Jan 14, 2025 (view filing)Jan 131 dayThornton Peter J.DirectorPPurchase+10.0K$8.05+$80.5K+10.6%104.1K after
Jan 14, 2025 (view filing)Jan 131 dayEnde Eric JDirectorPPurchase+30.0K$7.84+$235.2K+16.8%208.9K after
Dec 16, 2024 (view filing)Dec 133 daysMcHugh Thomas SChief Financial OfficerPPurchase+2.30K$10.44+$24.0K+2.7%87.8K after
Dec 12, 2024 (view filing)Dec 111 dayMcHugh Thomas SChief Financial OfficerPPurchase+5.00K$10.49+$52.5K+6.2%85.5K after
Dec 10, 2024 (view filing)Dec 6-94 daysDivis Gregory JChief Executive OfficerPPurchase+10.0K$9.97+$99.7KNew position10.0K after2 lots
Dec 10, 2024 (view filing)Dec 10Same dayGlass Geoffrey MichaelDirectorPPurchase+20.3K$9.84+$199.6K+36.5%75.9K after2 lots
Dec 10, 2024 (view filing)Dec 64 daysPalczuk LindaDirectorPPurchase+3.00K$10.19+$30.6K+4.7%66.4K after
Jan 16, 2024 (view filing)Jan 16Same dayMcHugh Thomas SChief Financial OfficerPPurchaseADSs+2.00K$14.50+$29.0K+2.5%80.5K after

Top 10 13F holders, Q4 2025

The largest institutional positions in Avadel Pharmaceuticals PLC at the end of Q4 2025; share changes are against Q3 2025.

See all 208 holders
Institutions holding AVDL in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.7,041,102$151.7M0.00%+67,444+1.0%Added
Vanguard Group Inc5,864,781$126.4M0.00%+258,499+4.6%Added
Gendell Jeffrey L4,769,357$102.8M1.79%−545,453−10.3%Reduced
Weiss Asset Management LP4,515,114$97.3M1.38%+4,515,114New
TIG Advisors, LLC3,859,122$83.2M4.01%+3,859,122New
Tudor Investment Corp Et Al2,983,541$64.3M0.35%+2,939,779+6,717.7%Added
FIL Ltd2,822,777$60.8M0.05%+2,822,777New
Vivo Capital, LLC2,684,109$57.8M3.74%00.0%Unchanged
State Street Corp2,278,301$49.1M0.00%−14,306−0.6%Reduced
Geode Capital Management, LLC2,156,356$46.5M0.00%−19,421−0.9%Reduced